immunization

(redirected from Active immunization)
Also found in: Dictionary, Thesaurus, Medical, Legal, Financial, Wikipedia.

immunization:

see immunityimmunity,
ability of an organism to resist disease by identifying and destroying foreign substances or organisms. Although all animals have some immune capabilities, little is known about nonmammalian immunity.
..... Click the link for more information.
; vaccinationvaccination,
means of producing immunity against pathogens, such as viruses and bacteria, by the introduction of live, killed, or altered antigens that stimulate the body to produce antibodies against more dangerous forms.
..... Click the link for more information.
.

Immunization

 

a method of creating artificial immunity in man and animals. Active and passive immunization are distinguished.

Active immunization involves injecting antigens into the body. The commonest form of active immunization is vaccination—that is, the use of vaccines, preparations obtained from microorganisms (bacteria, rickettsias, and viruses) or their metabolic products (toxins) for the specific prevention of infectious diseases in man and animals. Active immunization is produced by applying a preparation (for example, a vaccine) to the skin, by injecting it subcutaneously, intracutaneously, intramuscularly, intraperitoneally, or intravenously, or by administering it orally or by inhalation. The dose of the vaccine influences the efficacy of immunization (to a certain limit, the immunizing effect increases with increasing dosage; hence, optimum doses, determined experimentally, are used). The immunization schedule, the reactivity of the organism, and the quality of the preparation are important factors.

The antigen is usually injected several times to create immunity. A second immunization (reimmunization) is carried out no sooner than one or two weeks after the first, so that the antibodies and antibody-forming cells will not be neutralized by excess antigen and thereby reduce the strength of the growing immunity. Immunizations repeated at intervals of several months or years are very effective.

Antigens adsorbed on aluminum hydroxide, phosphates, or alums or mixed with mineral oils are frequently used for purposes of immunization. These substances, called adjuvants, intensify the immunizing effect of the antigen, bring about its gradual absorption from the injection site, and stimulate nonspecific antibody formation. Active immunization produces prolonged immunity (for a year or more) through the formation of specific antibodies and immune cells, and through the stimulation of nonspecific immunity factors.

Passive immunization is produced by injecting serum or serum fractions from the blood of immune animals and persons subcutaneously, intramuscularly, or, in certain emergencies, intravenously. Such preparations contain preformed antibodies, which neutralize toxin, inactivate the causative agent, and prevent the agent from spreading. Passive immunization creates temporary immunity (to a month). It is used to prevent disease in cases of contact with a source of infection (measles, diphtheria, tetanus, gas gangrene, plague, anthrax, influenza [seroprophylaxis] or, if the disease has already set in, to mitigate its course [serotherapy]). Sometimes combined immunization is used: first the immune serum is injected to help the patient cope with the infection, and then the vaccine is introduced in order to create a more stable immunity.

Homologous serums (that is, serums obtained from human blood) are preferred for the seroprophylaxis of infections in man. These serums generally do not provoke allergic reactions and are effective in infections (measles, infectious hepatitis) for which appropriate serums cannot be obtained from animals. Heterologous serums, or those obtained from animals (horse serum is used most frequently), may cause sensitization and provoke allergic reactions (anaphylactic shock, serum sickness). The use of heterologous serums is being curtailed. Seroprophylaxis with protein fractions (gamma globulin, polyglobulin and so forth) of human venous, placental, and abortion blood is commonly used instead.

Immunization is widely used against animal diseases caused by pathogenic viruses (foot-and-mouth disease, cattle plague), rickettsias (hydropericarditis), and bacteria (anthrax, blackleg, brucellosis). It is carried out in a planned regime, with account taken of the local conditions and the particular characteristics of the diseases.

A. KH. KANCHURIN and N. V. MEDUNITSYN

immunization

[‚im·yə·nə′zā·shən]
(immunology)
Rendering an organism immune to a specific communicable disease.
References in periodicals archive ?
Active immunization of heifers against luteinizing hormone-releasing hormone, human chorionic gonadotropin and bovine luteinizing hormone.
In spite of active immunization with recombinant DNA vaccine, some patients became infected with HBV infection.
The vaccine is also indicated in adults 50 years of age and older for active immunization for the prevention of pneumonia and invasive disease caused by the 13 Streptococcus pneumoniae serotypes contained in the vaccine (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F).
In contrast, active immunization aims to enhance uptake of S.
It may be mentioned here that as of January 2011, Menveo is registered in more than 40 countries for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y in people from 11 years of age.
In the European Union, Prevenar 13 is indicated for active immunization for the prevention of invasive pneumococcal disease caused by Streptococcus pneumoniae in adults aged 50 years and older caused by 13 Streptococcus pneumoniae serotypes.
The Food and Drug Administration has approved a new smallpox vaccine, ACAM2000, for active immunization against smallpox in individuals determined to be at high risk for smallpox infection.
The nasal mist is indicated for active immunization for the prevention of disease which is caused by influenza A and B viruses.
Prevenar 13 was previously prequalified for active immunization of infants and children from six weeks through 5 years of age against invasive pneumococcal disease, pneumonia and otitis media in August 2010.
Pfizer Inc today announced that the European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that TRUMENBA (Meningococcal Group B Vaccine) be granted marketing authorization in the European Union (EU) for active immunization of individuals 10 years and older to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB).
M2 EQUITYBITES-December 20, 2016-Pfizer passes EC's approval for Nimenrix (meningococcal group A, C, W-135 and Y conjugate vaccine) for active immunization against invasive meningococcal disease in infants
M2 PHARMA-December 20, 2016-Pfizer passes EC's approval for Nimenrix (meningococcal group A, C, W-135 and Y conjugate vaccine) for active immunization against invasive meningococcal disease in infants